According to the 4 th National Nutrition and Health Survey in 2002, the prevalence of hypertension in China was 18.8%. Although there are no recent updated nationwide data, it is believed that the prevalence of hypertension has increased substantially in the past decade to more than 200 million hypertensive patients in the most populous country in China. To fight against the growing risk of hypertension, three Chinese hypertension guidelines were compiled in the past two decades, respectively, in 1999, 2005, and 2011. The current guidance document for the management of hypertension was named "2010 Chinese hypertension guideline" but published in 2011. In this guideline, all five classes of antihypertensive drugs were recommended as possible initial and maintenance therapies. The goal of treatment was a systolic/diastolic blood pressure below 140/90 mm Hg in general, 130/80 mm Hg in various groups of high-risk patients, and 150/90 mm Hg in the elderly (≥65 years). With the recent publication of several national and international hypertension guidelines, the Chinese guideline is now being considered for updates
introduction From 2013 to 2014, several national [1, 2] and international [3, 4] hypertension guidelines were published. Although some of those guidelines did not change very much in the therapeutic management of hypertension, [1, 3] some others did have significant changes in the target blood pressure of treatment in general and in various subgroups of hypertensive patients. [2, 4] The current Chinese hypertension guideline was published in 2011, [5] and is now being reviewed for updates. The Chinese Hypertension League has recently given its approval to start updating the Chinese hypertension guideline. A guideline committee will soon form and convene later in 2015.
China is a fast-growing and aging nation with more than 200 million hypertensive patients. It would be useful to scrutinize what kind of guidelines the country will need to tackle the huge current and emerging cardiovascular risk of hypertension. The present review describes the challenges in the management of hypertension in China and the current Chinese hypertension guidelines and attempts to provide some insights into the future guidance documents for the management of hypertension in China.
challenGes in the manaGement of hypertension in china
In 1991 and 2002, two nationwide blood pressure surveys were conducted in China [ Table 1 ]. [6, 7] In 1991, about a million people of at least 15 years were surveyed.
[6] About 11.3% had a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or had used antihypertensive medication. The awareness, treatment, and control rates were 26.6%, 12.1%, and 2.8%, respectively. Of those who were aware of hypertension, the treatment rate was 45.5%. Of those who were treated, the control rate was 23.1%. In the 4 th National Health and Nutrition Survey in 2002, blood pressure was measured. [7] In this survey of 141,892 patients, the prevalence, treatment, and control rates of hypertension increased to 18.8%, 24.7%, and 6.1%, respectively, in comparison with the data in 1991. The treatment rate in hypertensive patients increased to 81.8%. The awareness and control rate in treated hypertensive patients remained virtually unaltered. In the elderly of at least 60 years, about half had hypertension, and the control rate was slightly higher than younger patients, mainly due to the higher awareness and treatment rate in hypertensive patients. [7] Until recently, there are no updated nationwide data on the prevalence of hypertension in China. Nonetheless, there were vast amounts of data from single-center regional surveys on hypertension and multicenter studies on other chronic diseases, such as diabetes mellitus. In a multicenter survey on the prevalence of diabetes mellitus, population samples of at least 20 years of age were randomly selected. The prevalence of hypertension was extraordinarily high, being 30.09% in men (n = 18,976) and 24.79% in women (n = 28,349). [8] This study might have, to some extent, overestimated the prevalence of hypertension. However, the prevalence of hypertension on the population level in China might indeed have had a substantial increase in the past few years, because the net increase in the number of elderly people (≥60 years) was more than 10 million each year since 2010. The number of elderly people in China now amounts to more than 200 million. This increasing trend is projected to continue for the next 20 years, resulting in at least 400 million people over 60 years of age. Simply for this reason, the number of hypertensive patients will increase rapidly to several hundred million in the next 20 years, because according to the recent survey, 60% of those people older than 60 years had hypertension. [9] In addition, lifestyle in China changes rapidly, and is characterized by high salt, high fat, high sugar and high-calorie diet; high anxiety and high stress in life and work; and low physical activity. This typical lifestyle will undoubtedly further worsen the situation. Hypertension will inevitably become an even more serious public health problem in the next 1-2 decades for China.
the chinese hypertension Guidelines
The first Chinese hypertension guideline was printed in a booklet in 1999 and had never been published anywhere. This guidance document was probably not so sophisticated, but played a role in improving the management of hypertension at that time in China. As mentioned above, the treatment rate of hypertension increased substantially from 45.5% in 1991 [6] to 81.8% in 2012 in patients who were aware of the disease. [7] The improvement to some extent could be attributed to the promotion of the first Chinese hypertension guidelines at the beginning of the 21 st century.
In 2004, the Chinese Hypertension League formed a guideline committee and for the first time published a guidance document for the management of hypertension in a supplemental issue of the Chinese Journal of Hypertension in 2005. [10] This document was prepared and published right after the first European Society of Hypertension guideline in 2003, [11] and was, therefore, influenced heavily by the European guidance. For instance, all five classes of antihypertensive drugs, namely calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, thiazide diuretics, and β-blockers, were recommended as possible choices for initial and maintenance antihypertensive therapy. This recommendation was distinct from that of the Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure (JNC 7), which was also published in 2003 and recommended thiazide diuretics as the only first-line therapy in the absence of compelling indications. [12] The current Chinese hypertension guideline was published in 2011 simultaneously in the Chinese Journal of Cardiology [5] and the Chinese Journal of Hypertension. [13] This guidance document was named as 2010 Chinese hypertension guideline and was considered an update of the 2005 guideline. This updated Chinese hypertension guideline was a comprehensive document and dealt with all issues of hypertension including secondary hypertension and various special populations, such as young and old age groups, patients with stroke, coronary heart disease, diabetes mellitus, and chronic kidney disease. For the principles of antihypertensive treatment, the recommendations included low-dose initiation, long-acting medication, combination therapy, and individualization. For the choice of antihypertensive drugs, the guideline continued to recommend all five classes of antihypertensive drugs. In the meantime, because the dihydropyridine calcium-channel blockers provided the best evidence from controlled clinical trials in China, [14] [15] [16] [17] and are more efficacious in lowering blood pressure in the Chinese population, [18] this class of drugs was listed in the first place among the recommended drugs. [5, 13] After the publication of the current Chinese hypertension guideline, the principles of long-acting medication and combination therapy were actively promoted, respectively, by working on two specific guidance documents in relation to antihypertensive therapy. One was the China science advisory on the role of morning blood pressure monitoring in the management of hypertension published in 2014. [19] Short-acting drugs are still widely used in the management of hypertension and might be the reason for the low control rate of hypertension, [9] especially when the efficacy was evaluated in the trough hours, usually in the morning. By measuring blood pressure in the morning before drug intake, a patient is more likely to be able to recognize the difference in blood pressure control between short-and long-acting drugs, and may, therefore, change from short-to long-acting antihypertensive drugs. In the past few years, this campaign has led to a substantial increase in the use of long-acting drugs in China.
Another guidance document was the China consensus on the use of single-pill combination antihypertensive therapy in the management of hypertension published in 2012. [20] According to a recent survey, although the control rate of hypertension was only 30.6%, the use of combination antihypertensive therapy remained low, being 45.9% in patients seen in big hospitals in big cities. [21] Single-pill combination of currently recommended antihypertensive drugs, such as inhibitors of the renin-angiotensin system with a calcium channel blocker or a thiazide diuretic, became available in China in the past decade. Although there is growing evidence in the Chinese population that use of single-pill combination antihypertensive drugs may significantly improve efficacy and tolerability, [22, 23] these drugs are still insufficiently used in treating hypertension. Thiazide diuretic as a component of these single-pill combination drugs could be a reason. [23] Single-pill combination of an inhibitor of the renin-angiotensin system with a calcium-channel blocker might change the situation in the future. [22] Low-dose initiation is actually a tradition of the use of antihypertensive drugs in China. This style may have led to the under-use of antihypertensive drugs and hence to the low control rate of hypertension. [9] The current European Society of Hypertension [3] and the American guidelines [2] recommend the use of full dose or maximum dose of antihypertensive drugs regardless of mono-or combination therapy. This change might help inadequate dosing of antihypertensive drugs.
Individualized use of medication relies on the expertise of physicians. Every physician can do it, but many do it differently. For now, what we can and should do is adhere to the principles of indication and contraindication, with the emerging molecular and other biological techniques, individualized or personalized therapy can be achieved in the future.
In the current Chinese hypertension guideline, [5, 13] the goal of antihypertensive treatment was defined according to age and associated diseases, such as diabetes mellitus, chronic kidney disease, and coronary heart disease. In general, the goal was a systolic/diastolic blood pressure below 140/90 mm Hg, including those with a history of stroke. However, in patients with the abovementioned diseases, the goal was below 130/80 mm Hg. In patients of 65 years or older, the goal was below 150/90 mm Hg. a multidimensional approach for future manaGement of hypertension in china
We do not know what the next Chinese hypertension guidelines will look like. However, we can always tell what we would like. We apparently need novel strategies in fighting against hypertension. Otherwise, we may fight a losing war. A strategic approach is to substantially simplify the guidelines, which was done in the JNC-8 guidance document. [2] Such an approach had also been recently proposed and discussed in China [ Figure 1 ]. [24] Treating blood pressure to the target level should be the focus of antihypertensive therapy (vertical axis). In truly uncontrolled hypertension, disease severity should be evaluated by measuring the function and structure of the vascular system and the target organs, and then specific interventions and treatment can be considered (horizontal axis). Those patients with characteristics suggestive of secondary hypertension or specific pathogenesis or pathophysiology should undergo screening for secondary causes of hypertension (lateral axis). Adapted with permission from pulse 2015;3:14-20.
Every "normotensive" person should measure blood pressure at home regularly at least once a year. Hypertension can then be diagnosed within a year of onset and treated timely and efficiently. Uncontrolled patients will be evaluated by ambulatory blood pressure monitoring for the identification of those with truly uncontrolled hypertension [25] and by advanced imaging and nonimaging techniques for the detection of target organ damage and arterial lesions. These evaluations will provide evidence of compelling indications for specific interventions and treatment. Some patients might show characteristics suggestive of diseases behind or causes of high blood pressure, and hence undergo an on-target screening for these diseases and causes of hypertension [ Table 2 ]. Some of these diseases or causes can be treated specifically, although hypertension cannot always be cured. We have classified hypertension as secondary and primary for almost a century. However, with the current advanced medical technology, this approach for classification is outdated. It is time to classify hypertension according to the diseases or characteristics, as illustrated in Table 2 , and to treat hypertension accordingly.
The new Chinese hypertension guidelines should focus on solutions for decreasing the disease burden of hypertension and for the improvement in the management of hypertension in China.
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